Communiqués Sol-Gel Technologies Ltd. Börse Stuttgart

Actions

4SG

IL0011417206

Temps Différé Börse Stuttgart Autres places de cotation 09:13:21 01/07/2024			Varia. 5j.	Varia. 1 janv.
0,795 ^EUR	+1,92%		-5,45%	-27,78%

28/05	Sol-Gel Technologies reçoit un avis de non-conformité du Nasdaq	MT
20/05	SOL-GEL TECHNOLOGIES LTD. : HC Wainwright persiste à l'achat	ZM

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice	28/05	AQ
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates	20/05	AQ
Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel	16/05	AQ
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream	01/04	AQ
Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments	13/03	AQ
Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study	30/11	AQ
Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610	28/11	AQ
Sol Gel Technologies : INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K - Form 6-K	20/11	PU
Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update	09/11	AQ
Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference	30/08/23	AQ
Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update	10/08/23	AQ
Sol Gel Technologies : NOTICE OF ANNUAL MEETING OF SHAREHOLDERS - Form 6-K	21/06/23	PU
Sol Gel Technologies : NOTICE OF ANNUAL MEETING OF SHAREHOLDERS - Form 6-K	14/06/23	PU
Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada	06/06/23	AQ
Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update	12/05/23	AQ
Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference	20/03/23	AQ
Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments	10/03/23	AQ
Sol Gel Technologies : NOTICE OF SPECIAL MEETING OF SHAREHOLDERS - Form 6-K	01/03/23	PU
Sol Gel Technologies : Gel Corporate Presentation	02/02/23	PU
Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings	30/01/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Sol-Gel Technologies Ltd. Börse Stuttgart

Actions

4SG

IL0011417206

Communiqués

Filtres